Uncategorized Archives - Page 12 of 151

TuesdayAug 19, 2025 9:45 am

Lantern Pharma Inc. (NASDAQ: LTRN) Releases Latest AI Breakthrough for Central Nervous System (‘CNS’) Drug Development with predictBBB.ai (TM): A High-Accuracy Open-Access AI Drug Development Tool

Lantern Pharma has publicly launched predictBBB.ai (TM), its AI-driven module for predicting small-molecule blood-brain barrier permeability. The tool achieves 94% prediction accuracy, with 95% sensitivity and 89% specificity, based on real-time ensemble machine learning. Powered by Lantern’s vast molecular features data lake and ensemble algorithms, the platform sets a new computational benchmark for CNS drug discovery. Lantern hosts additional predictive and analytical modules in development, leveraging its large-scale data infrastructure and algorithmic approach. The tool is publicly accessible through a freemium model, aiming to drive adoption, strategic partnerships, and accelerate CNS therapeutic development. Lantern Pharma subsidiary Starlight Therapeutics secures FDA IND clearance…

TuesdayAug 19, 2025 9:45 am

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): How a $500K Device Could Reshape the $8.7 Billion Breast Imaging Market

IzoView Breast CT targets aggressive market displacement with up to 67% lower pricing than competing breast CT systems, positioning at $500K versus competitors priced up to $1.5 million True 360-degree 3D imaging without compression positioned to bridge the clinical gap between standard screening and MRI, offering 100x greater spatial resolution than MRI at significantly lower cost Platform approach enables 14 potential future indications across screening, diagnosis, monitoring, and treatment planning through software upgrades, creating scalable revenue expansion without hardware replacement Every year, outdated imaging technologies underperform for the roughly half of women undergoing breast cancer screening who have dense breast…

FridayAug 15, 2025 12:45 pm

Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy

Ricin toxin is a potent biothreat, so lethal that even a dose the size of a grain of salt can be fatal within 48 to 72 hours. RiVax(R) is a subunit protein vaccine that incorporates Soligenix’s ThermoVax(R) technology, which eliminates the need for cold-chain storage. Soligenix reports that the RiVax antigen has been shown to be safe in phase 1 studies in humans, with future steps including pivotal animal efficacy studies. With global security threats driving demand for advanced biodefense solutions, Soligenix (NASDAQ: SNGX) is advancing RiVax(R), a heat-stable recombinant vaccine candidate aimed at protecting against deadly ricin toxin exposure.…

FridayAug 08, 2025 9:00 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF): The Cancer Detection Revolution That Could Make Breast Cancer Deaths Preventable

Izotropic’s IzoView Breast CT Imaging System represents a breakthrough in dedicated breast imaging technology, addressing persistent limitations in conventional screening methods through proprietary hardware and software FDA regulatory pathway alignment clears the path for a pivotal U.S. clinical study, with the company completing a comprehensive 150-page strategic business plan and advanced financial modeling for commercialization Strategic awareness initiatives including dedicated breastct.com platform and podcast series position the company for market education as breast CT technology emerges as the next generation of cancer detection The medical community stands at the threshold of what could become the most significant advancement in cancer…

ThursdayAug 07, 2025 10:30 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Advancing Next-Gen Breast Cancer Imaging

Breast cancer continues to be the most commonly diagnosed cancer among U.S. women, excluding nonmelanoma skin cancer Izotropic is preparing to revolutionize breast cancer imaging with its flagship IzoView Breast CT Imaging System In anticipation of future commercialization, Izotropic is initiating a strategic awareness and engagement campaign Accurate detection and diagnosis remain critical challenges in the fight against breast cancer, especially for women with dense breast tissue where mammography falls short. Izotropic (CSE: IZO) (OTCQB: IZOZF) is at the forefront of addressing these gaps through its IzoView Breast CT Imaging System, a contrast-enhanced CT platform designed for enhanced screening precision. The company…

ThursdayAug 07, 2025 9:00 am

Lantern Pharma Inc. (NASDAQ: LTRN) Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule

The trial targets never-smoker non-small cell lung cancer (“NSCLC”) patients, a group with limited treatment options. Japan’s high incidence of never-smoker NSCLC makes it a strategic region for the trial. LP-300 is being tested alongside standard chemotherapy agents in patients who have relapsed after tyrosine kinase inhibitor therapy. Lantern's AI-driven approach may help identify and accelerate development of therapies in underserved cancer markets. Additional trial data from Taiwan and the U.S. is expected later in Q3 2025. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has completed targeted patient…

WednesdayAug 06, 2025 12:10 pm

Lantern Pharma Inc. (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations

Lantern Pharma has introduced an AI-powered module within its RADR(R) platform to assess DDA-DDRi combination therapies. The module uses genomic, transcriptomic, and clinical data, to predict treatment synergy and patient response, and supported the design of Lantern’s FDA-cleared Phase 1B/2 trial in triple-negative breast cancer. A review of 221 clinical trials informed the development of the predictive algorithm. Non-PARP DDRi combinations with DNA-damaging agents showed strong outcomes in specific cancer subtypes. Lantern is evaluating licensing opportunities to commercialize the module for broader oncology use. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine…

WednesdayAug 06, 2025 11:30 am

HeartBeam Inc. (NASDAQ: BEAT) FDA-Cleared System Provides Momentum as Company Moves to Innovate Cardiac Care

The FDA-cleared HeartBeam system enables patients and physicians to access significant arrhythmia data outside traditional clinical settings. The HeartBeam system, credit card–sized and fully portable, represents a breakthrough in ambulatory cardiac care. Beyond ambulatory arrhythmia assessment, the platform is poised for future advancements, including synthesized 12-lead ECG generation. Foundational clearance from the U.S. Food and Drug Administration (“FDA”) for its patented HeartBeam system has proved pivotal for HeartBeam (NASDAQ: BEAT), a cardiac technology company focused on transforming the cardiac-care space (https://ibn.fm/0TAG4). The first cable-free, high-fidelity ECG device that captures the heart’s electrical activity from three distinct directions, the HeartBeam system…

WednesdayAug 06, 2025 10:50 am

Nutriband Inc. (NASDAQ: NTRB) Navigates Drug-Delivery Challenges with Innovation in Abuse-Deterrent Tech

Drug delivery plays a critical role in modern healthcare, but when it comes to potent opioids such as fentanyl, the stakes are particularly high Nutriband is developing Aversa(TM), a proprietary abuse-deterrent transdermal technology designed to prevent diversion, misuse, abuse and accidental exposure Nutriband’s Aversa(TM) fentanyl patch is estimated to have a market potential of $80 million to $200 million annually within five years of launch Developing safe, effective and abuse-deterrent delivery systems for controlled substances such as fentanyl is a formidable challenge, and Nutriband (NASDAQ: NTRB) is positioning itself at the forefront of that effort. The company is pioneering transdermal technologies to…

TuesdayAug 05, 2025 11:15 am

HeartBeam Inc.’s (NASDAQ: BEAT) Two New U.S. Patents Power Next Generation of Cardiac Diagnostics

Two newly issued patents mark a strategic advancement in HeartBeam’s proprietary technology. The first patent protects the company’s credit card–sized, cable-free 3D ECG device designed to capture high-fidelity electrical signals from three noncoplanar directions. The second patent covers the company’s rhythm analysis algorithm by continuously analyzing signal input. HeartBeam (NASDAQ: BEAT), a cardiac technology company, has secured two new U.S. patents that significantly enhance its intellectual property portfolio and strengthen its position in cardiac monitoring technology (https://ibn.fm/6xni4). The company, focused on delivering powerful, personalized insights into heart health through its innovative 3D ECG platform, now holds more than 20 U.S.…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Lantern Pharma Inc. (NASDAQ: LTRN) Releases Latest AI Breakthrough for Central Nervous System (‘CNS’) Drug Development with predictBBB.ai (TM): A High-Accuracy Open-Access AI Drug Development Tool

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): How a $500K Device Could Reshape the $8.7 Billion Breast Imaging Market

Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF): The Cancer Detection Revolution That Could Make Breast Cancer Deaths Preventable

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Advancing Next-Gen Breast Cancer Imaging

Lantern Pharma Inc. (NASDAQ: LTRN) Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule

Lantern Pharma Inc. (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations

HeartBeam Inc. (NASDAQ: BEAT) FDA-Cleared System Provides Momentum as Company Moves to Innovate Cardiac Care

Nutriband Inc. (NASDAQ: NTRB) Navigates Drug-Delivery Challenges with Innovation in Abuse-Deterrent Tech

HeartBeam Inc.’s (NASDAQ: BEAT) Two New U.S. Patents Power Next Generation of Cardiac Diagnostics

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search